A Study to Determine the Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing bictégravir, Emtricitabine and ténofovir alafénamide

Inclusion Criteria: * Male HIV-1 infected subjects * Age \> or = 18 years old * Currently receiving as first line a stable ARV regimen containing bictegravir (at 50 mg once a day) and two nucleoside reverse transcriptase inhibitors, tenofovir alafenamide/emtricitabine (Biktarvy) * HIV RNA \<50 Cp/mL, undetectable 6 months after treatment initiation and confirmed and 12 months after treatment initiation. * Normal laboratory value of TP and TCA and platelets numbers at screening * Written and informed consent signed by the person and the investigator (no later than the day of pre-inclusion and prior to any examination realized in the frame of the research / study / trial) (article L1122-1-1 of the Public Health Code) * Person affiliated or beneficiary of a social security scheme (article L1121-11 of the Public Health Code) (State Medical Aid or AME is not a social security scheme) Exclusion Criteria: * Single HIV-2 infection * Biopsies contraindication, taking anticoagulant and antiplatelet drugs are not allowed * Haemophilia * Symptomatic sexually transmitted infection * Being under guardianship or trusteeship mandate for future protection * Participate to another research involving human person, categories 1 or 2, * Associated treatments : carbamazepine, oxcarbazepine, phenytoin, phenobarbital, rifampicin, St. John's Wort.